Mouse NBL1 / DAN Protein (His Tag)

Neuroblastoma, suppression of tumorigenicity 1 Protein Datasheet

NBL1 / DAN Protein Product Information

• Synonym: RP23-65B16.3, D4H1S1733E, DAN, Dana, NO3
• Protein Construction: A DNA sequence encoding the mouse NBL1 (Q61477) (Met 1-Asp 178) was expressed, with a C-terminal polyhistidine tag.
• Source: Mouse
• Expression Host: Human Cells

NBL1 / DAN Protein QC Testing

• Purity: > 95 % as determined by SDS-PAGE.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Ala 17
• Molecular Mass: The secreted recombinant mouse NBL1 comprises 173 amino acids and has a calculated molecular mass of 18.8 kDa. As a result of glycosylation, the apparent molecular mass of the recombinant protein is approximately 28 kDa in SDS-PAGE under reducing conditions.
• Formulation: Lyophilized from sterile PBS , pH 7.4
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: NBL1 / DAN protein

NBL1 / DAN Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

NBL1 / DAN Protein Description

Differential screening-selected gene aberrative in neuroblastoma (DAN) originally isolated from a normal lung cDNA library, is a the prototypical member of the DAN family of secreted glycoproteins. There are at least five mammalian protein members in the evolutionarily conserved Dan family including DAN, Gremlin/DRM, Cer1 (Cerberus-related), Dante and PRDC (protein related to DAN and cereberus), and share the C-terminal cystine-knot motif. As a secreted glycoprotein, DAN acts as the BMPs (bone morphogenetic protein) antagonist by binding to BMPs and preventing their interactions with signaling receptor complexes, and accordingly regulates the processes of embryonic development and tissue differentiation. In addition, it has been reported that DAN also acts as an inhibitor of cell cycle progression and monocyte chemotaxis, and is closely involved in human neuroblastoma differentiation. DAN thus is regarded as a novel candidate of tumour suppressor.

References

1. Enomoto H. et al., 1994, Oncogene. 9: 2785-91.
2. Nakamura Y. et al., 1997, Eur J Cancer. 33: 1986-90.
3. Dionne MS. et al., 2001, Mol Cell Biol. 21: 636-43.
4. Shinbo J. et al., 2002, Biochem Biophys Res Commun. 295: 501-7.
5. Chen B. et al., 2004, J Immunol. 173: 5914-7.